Fiserv earnings missed by $0.61, revenue fell short of estimates
Investing.com - H.C. Wainwright has lowered its price target on Reviva Pharmaceuticals (NASDAQ:RVPH) to $4.00 from $11.00 while maintaining a Buy rating, citing dilutive financings as the primary reason for the reduction. Currently trading at $0.68 with a market cap of $65 million, the stock sits well below analyst targets ranging from $2 to $16. InvestingPro data reveals three analysts have recently revised their earnings expectations upward for the upcoming period.
The research firm noted that Reviva management plans to meet with FDA reviewers this quarter to discuss the approval path for brilaroxazine, the company’s schizophrenia treatment candidate. If the FDA does not require a confirmatory Phase 3 trial, Reviva could potentially submit a New Drug Application (NDA) in the second quarter of 2026. While the company holds more cash than debt on its balance sheet, InvestingPro analysis indicates weak financial health scores, with short-term obligations exceeding liquid assets.
H.C. Wainwright indicated that FDA feedback represents a meaningful near-term catalyst, while NDA submission and acceptance would constitute a significant risk-mitigation event that could position Reviva for potential brilaroxazine approval in the first half of 2027.
The firm maintained its view that a confirmatory pivotal trial would likely be needed, based on established precedent for novel atypical antipsychotic drugs. Under this base case scenario, H.C. Wainwright expects brilaroxazine regulatory submission in late 2027, with potential approval and launch in late 2028.
The analyst highlighted brilaroxazine’s positive Phase 3 data from the RECOVER trial released in late 2023, noting that the drug appears more potent in schizophrenia than lumateperone, a competing treatment. Despite showing strong returns over the past three months, the stock remains down 68% year-to-date. Get access to 10+ additional exclusive InvestingPro insights and real-time financial metrics to make more informed investment decisions.
In other recent news, Reviva Pharmaceuticals Holdings, Inc. announced the pricing of a public offering that aims to raise approximately $9 million in gross proceeds. The offering includes 27 million shares of common stock priced at $0.335 per share, each accompanied by Series E and Series F warrants. This move is intended to support the company’s research and development activities and general corporate purposes. Additionally, the board of directors approved an amendment to the company’s bylaws, reducing the quorum required for shareholder meetings to one-third of the voting power. This change is effective immediately and applies unless otherwise specified by law or the company’s governing documents. In a separate development, Benchmark has lowered its price target for Reviva Pharmaceuticals from $14.00 to $7.00 while maintaining a Speculative Buy rating. The adjustment comes amid uncertainties surrounding an upcoming FDA meeting scheduled for the fourth quarter of 2025, which will discuss the company’s New Drug Application for its schizophrenia treatment, Brilaroxazine.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.